Mirum Pharmaceuticals: After Phase 2 Miss, An iBAT Inhibitor On Deck To Drive Value

3d ago, source:

FDA approved Mirum Pharmaceuticals' Limvarli for treatment of cholestatic pruritus in patients with PFIC. Learn why I rate ...

Analyst Ratings For Mirum Pharmaceuticals

9d ago, source:

Across the recent three months, 9 analysts have shared their insights on Mirum Pharmaceuticals (NASDAQ:MIRM), expressing a ...

Mirum Pharmaceuticals, Inc. (MIRM) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

1d ago, source:

Mirum Pharmaceuticals (MIRM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Stifel Initiates Coverage of Mirum Pharmaceuticals (MIRM) with Buy Recommendation

8d ago, source: Fintel on MSN

Fintel reports that on April 17, 2024, Stifel initiated coverage of Mirum Pharmaceuticals (NasdaqGM:MIRM) with a Buy ...

Buy Rating Affirmed for Mirum Pharmaceuticals Amidst Strategic Positioning and Treatment Breakthroughs

9d ago, source:

Dae Gon Ha, an analyst from Stifel Nicolaus, has initiated a new Buy rating on Mirum Pharmaceuticals (MIRM). Dae Gon Ha has given his Buy ...

Medication helping local boy cope with ALGS recommended to be more widely available in Canada

21h ago, source: Chatham Daily News

“He’s been able to have a real, full, happy life.” ...

3 Potential Biopharma Buyout Targets

3d ago, source:

Drug blockbusters facing key patent expirations and Big Pharma's surplus of cash suggest increased M&A volume in the coming ...

Shanghai Jemincare Pharmaceuticals patents new androgen receptor antagonists

1d ago, source: BioWorld

Shanghai Jemincare Pharmaceuticals Co. Ltd. has disclosed phosphorus-containing compounds acting as androgen receptor antagonists reported to be useful for the treatment of cancer, alopecia, acne, ...

MiMedx Group, Cyclacel Pharmaceuticals, Predictive Oncology among healthcare movers

on MSN ago, source:

NewGenIvf Group (NIVF) +18%. Cidara Therapeutics (CDTX) +13%. Predictive Oncology (POAI) +10%. Zura Bio (ZURA) +6%. Losers: Cyclacel Pharmaceuticals (CYCC) -27%. 2seventy bio (TSVT) -12%.

Progressive Familial Intrahepatic Cholestasis Treatment Market Projected to Reach $156.14 million by 2030 - Exclusive Report by 360iResearch

7d ago, source:

The report titled "Progressive Familial Intrahepatic Cholestasis Treatment Market by Drug Type (Cholestyramine, Rifampicin, ...